In contrast to hybrid closed-loop systems, the FCL system has no requirement for user input at mealtimes and reduces the burden of managing diabetes.1 The FCL system has been shown to improve glycemic control for adults with type 1 diabetes and suboptimal glycemic control and adults with type 2 diabetes compared to standard insulin therapy, while also being safe with no increased time spent in hypoglycemia.1,2. The gene discussed is INS; the disease is type 2 diabetes mellitus.